Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Subklewe

Showing results (91-100 of 244) with videos related to

Pageof 25
Sort By:
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2015
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AMLFelix S Lichtenegger, Isabell Kondla, Michael Krempasky, et al.
European Radiology Experimental|November 17, 2020
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directionsMarcus Unterrainer, Michael Ruzicka, Matthias P Fabritius, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Blood|October 18, 2022
WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in miceMaryam Ghalandary, Yuqiao Gao, Diana Amend, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Hemasphere|October 3, 2022
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall SurvivalMichael Winkelmann, Kai Rejeski, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Neurology|March 30, 2022
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T CellsPhilipp Karschnia, Kai Rejeski, Michael Winkelmann, et al.
Pageof 25

Showing results (91-100 of 244) with videos related to

Sort By:
Pageof 25
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|November 22, 2025
Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-CellsMichael Winkelmann, Philipp Achhammer, Viktoria Blumenberg, et al.
Cancer Immunology, Immunotherapy : CII|September 18, 2015
RNA and protein expression of herpesvirus entry mediator (HVEM) is associated with molecular markers, immunity-related pathways and relapse-free survival of patients with AMLFelix S Lichtenegger, Isabell Kondla, Michael Krempasky, et al.
European Radiology Experimental|November 17, 2020
PET/CT imaging for tumour response assessment to immunotherapy: current status and future directionsMarcus Unterrainer, Michael Ruzicka, Matthias P Fabritius, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 13, 2022
Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapyMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Blood|October 18, 2022
WT1 and DNMT3A play essential roles in the growth of certain patient AML cells in miceMaryam Ghalandary, Yuqiao Gao, Diana Amend, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|May 15, 2023
Staging of lymphoma under chimeric antigen receptor T-cell therapy: reasons for discordance among imaging response criteriaMichael Winkelmann, Viktoria Blumenberg, Kai Rejeski, et al.
Hemasphere|October 3, 2022
Chimeric Antigen Receptor T-cell Therapy: Imaging Response Criteria and Relation to Progression-free and Overall SurvivalMichael Winkelmann, Kai Rejeski, Viktoria Blumenberg, et al.
Frontiers in Oncology|September 26, 2022
Lymphoma tumor burden before chimeric antigen receptor T-Cell treatment: RECIL vs. Lugano vs. metabolic tumor assessmentMichael Winkelmann, Veit L Bücklein, Viktoria Blumenberg, et al.
Cancer Treatment and Research Communications|January 7, 2026
Impact of spleen volume and volume change in non-Hodgkin lymphoma treated with chimeric antigen receptor t-cell therapyChristina Quell, Wolfgang G Kunz, Viktoria Blumenberg, et al.
Neurology|March 30, 2022
Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T CellsPhilipp Karschnia, Kai Rejeski, Michael Winkelmann, et al.
Pageof 25